Acetylsalicylic acid enhances the anti-inflammatory effect of fluoxetine through inhibition of NF-κB, p38-MAPK and ERK1/2 activation in lipopolysaccharide-induced BV-2 microglia cells

Neuroscience

Volumn 275, Issue , 2014, Pages 296-304

  Yang, J M ^c   Rui, B B ^a   Chen, C ^d   Chen, H ^a   Xu, T J ^b   Xu, W P ^b   Wei, W ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

^c ANHUI PROVINCIAL CANCER HOSPITAL   (China)

^d INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

Acetylsalicylic acid; Depression; Fluoxetine; Microglia

Indexed keywords

ACETYLSALICYLIC ACID; FLUOXETINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SEROTONIN; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; LIPOPOLYSACCHARIDE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BV 2 MICROGLIAL CELL; CELL ACTIVATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; ENZYME ACTIVITY; INHIBITION KINETICS; MICROGLIA; NERVE CELL STIMULATION; NEUROMODULATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; METABOLISM; MOUSE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ASPIRIN; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUOXETINE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; MICE; MICROGLIA; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 84903949772     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.06.016     Document Type: Article

References (61)

1. Abdel-Salam O.M., Baiuomy A.R., Arbid M.S. Studies on the anti-inflammatory effect of fluoxetine in the rat. Pharmacol Res 2004, 49:119-131.
2. Amor S., Puentes F., Baker D., Van Der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010, 129:154-169.
3. Anderson G., Maes M., Berk M. Inflammation-related disorders in the tryptophan catabolite pathway in depression and somatization. Adv Protein Chem Struct Biol 2012, 88:27-48.
4. Arana-Argaez V.E., Delgado-Rizo V., Pizano-Martinez O.E., Martinez-Garcia E.A., Martin-Marquez B.T., Munoz-Gomez A., Petri M.H., Armendariz-Borunda J., et al. Inhibitors of MAPK pathway ERK1/2 or p38 prevent the IL-1{beta}-induced up-regulation of SRP72 autoantigen in Jurkat cells. J Biol Chem 2010, 285:32824-32833.
5. Babcock T.A., Carlin J.M. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine 2000, 12:588-594.
6. Boldrini M., Underwood M.D., Hen R., Rosoklija G.B., Dwork A.J., John Mann J., Arango V. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 2009, 34:2376-2389.
7. Brunello N., Alboni S., Capone G., Benatti C., Blom J.M., Tascedda F., Kriwin P., Mendlewicz J. Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. Int Clin Psychopharmacol 2006, 21:219-225.
8. Carpintero R., Brandt K.J., Gruaz L., Molnarfi N., Lalive P.H., Burger D. Glatiramer acetate triggers PI3Kdelta/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes. Proc Natl Acad Sci USA 2010, 107:17692-17697.
9. Dantzer R., O'connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
10. Fitzgerald P., Cassidy Eugene M., Clarke G., Scully P., Barry S., Quigley Eamonn M.M., Shanahan F., Cryan J., et al. Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity. Neurogastroenterol Motil 2008, 20:1291-1297.
11. Garden G.A., Moller T. Microglia biology in health and disease. J Neuroimmune Pharmacol 2006, 1:127-137.
12. Garrison G.D., Levin G.M. Factors affecting prescribing of the newer antidepressants. Ann Pharmacother 2000, 34:10-14.
13. Goshen I., Kreisel T., Ben-Menachem-Zidon O., Licht T., Weidenfeld J., Ben-Hur T., Yirmiya R. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 2008, 13:717-728.
14. Griffiths M.R., Gasque P., Neal J.W. The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol 2009, 68:217-226.
15. Hashioka S. Anti-neuroinflammatory effects of psychopharmaceuticals: further than monoamine modulators. Mini Rev Med Chem 2011, 11:553-554.
16. Hashioka S., Klegeris A., Monji A., Kato T., Sawada M., Mcgeer P.L., Kanba S. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol 2007, 206:33-42.
17. Hashioka S., Mcgeer P.L., Monji A., Kanba S. Anti-inflammatory effects of antidepressants: possibilities for preventives against Alzheimer's disease. Cent Nerv Syst Agents Med Chem 2009, 9:12-19.
18. Hinwood M., Morandini J., Day T.A., Walker F.R. Evidence that microglia mediate the neurobiological effects of chronic psychological stress on the medial prefrontal cortex. Cereb Cortex 2012, 22:1442-1454.
19. Horikawa H., Kato T.A., Mizoguchi Y., Monji A., Seki Y., Ohkuri T., Gotoh L., Yonaha M., et al. Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium. Progress in neuro-psychopharmacology & biological psychiatry 2010, 34:1306-1316.
20. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71:171-186.
21. Hyphantis T., Kotsis K., Tsifetaki N., Creed F., Drosos A.A., Carvalho A.F., Voulgari P.V. The relationship between depressive symptoms, illness perceptions and quality of life in ankylosing spondylitis in comparison to rheumatoid arthritis. Clin Rheumatol 2013, 32:635-644.
22. Kempermann G., Krebs J., Fabel K. The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. Curr Opin Psychiatry 2008, 21:290-295.
23. Kim S.H., Smith C.J., Van Eldik L.J. Importance of MAPK pathways for microglial pro-inflammatory cytokine IL-1 beta production. Neurobiol Aging 2004, 25:431-439.
24. Koistinaho M., Koistinaho J. Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia 2002, 40:175-183.
25. Lim C.M., Kim S.W., Park J.Y., Kim C., Yoon S.H., Lee J.K. Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res 2009, 87:1037-1045.
26. Liu D., Wang Z., Liu S., Wang F., Zhao S., Hao A. Anti-inflammatory effects of fluoxetine in lipopolysaccharide (LPS)-stimulated microglial cells. Neuropharmacology 2011, 61:592-599.
27. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 2008, 29:287-291.
28. Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuro-psychopharmacol Biol Psychiatry 2011, 35:664-675.
29. Maes M., Meltzer H.Y., Scharpe S., Bosmans E., Suy E., De Meester I., Calabrese J., Cosyns P. Relationships between lower plasma l-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res 1993, 49:151-165.
30. Maes M., Scharpe S., Meltzer H.Y., Okayli G., Bosmans E., D'hondt P., Vanden Bossche B.V., Cosyns P. Increased neopterin and interferon-gamma secretion and lower availability of l-tryptophan in major depression: further evidence for an immune response. Psychiatry Res 1994, 54:143-160.
31. Maes M., Mihaylova I., Ruyter M.D., Kubera M., Bosmans E. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett 2007, 28:826-831.
32. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., Kubera M., Bob P., et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009, 24:27-53.
33. Maneglier B., Rogez-Kreuz C., Spreux-Varoquaux O., Malleret B., Therond P., Samah B., Drouet I., Dormont D., et al. Comparative effects of two type I interferons, human IFN-alpha and ovine IFN-tau on indoleamine-2,3-dioxygenase in primary cultures of human macrophages. Fundam Clin Pharmacol 2007, 21:29-34.
34. Mankan A.K., Lawless M.W., Gray S.G., Kelleher D., Mcmanus R. NF-kappaB regulation: the nuclear response. J Cell Mol Med 2009, 13:631-643.
35. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
36. Montgomery S.A. Efficacy and safety of the selective serotonin reuptake inhibitors in treating depression in elderly patients. Int Clin Psychopharmacol 1998, 13(Suppl. 5):S49-S54.
37. Muller N., Myint A.M., Schwarz M.J. Inflammatory biomarkers and depression. Neurotox Res 2011, 19:308-318.
38. Myint A.M., Leonard B.E., Steinbusch H.W., Kim Y.K. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 2005, 88:167-173.
39. O'Sullivan J.B., Ryan K.M., Curtin N.M., Harkin A., Connor T.J. Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int J Neuropsychopharmacol 2009, 12:687-699.
40. Quiniou C., Kooli E., Joyal J.S., Sapieha P., Sennlaub F., Lahaie I., Shao Z., Hou X., et al. Interleukin-1 and ischemic brain injury in the newborn: development of a small molecule inhibitor of IL-1 receptor. Semin Perinatol 2008, 32:325-333.
41. Rahola J.G. Somatic drugs for psychiatric diseases: aspirin or simvastatin for depression?. Curr Neuropharmacol 2012, 10:139-158.
42. Ropert C., Closel M., Chaves A.C., Gazzinelli R.T. Inhibition of a p38/stress-activated protein kinase-2-dependent phosphatase restores function of IL-1 receptor-associate kinase-1 and reverses Toll-like receptor 2- and 4-dependent tolerance of macrophages. J Immunol 2003, 171:1456-1465.
43. Roumestan C., Michel A., Bichon F., Portet K., Detoc M., Henriquet C., Jaffuel D., Mathieu M. Anti-inflammatory properties of desipramine and fluoxetine. Respir Res 2007, 8:35.
44. Sarkar F.H., Li Y., Wang Z., Kong D. NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 2008, 27:293-319.
45. Schwartz M., Shechter R. Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol 2010, 6:405-410.
46. Shelton R.C., Claiborne J., Sidoryk-Wegrzynowicz M., Reddy R., Aschner M., Lewis D.A., Mirnics K. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 2011, 16:751-762.
47. Song C., Halbreich U., Han C., Leonard B.E., Luo H. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 2009, 42:182-188.
48. Studer R.K., Gilbertson L.G., Georgescu H., Sowa G., Vo N., Kang J.D. P38 MAPK inhibition modulates rabbit nucleus pulposus cell response to IL-1. J Orthop Res 2008, 26:991-998.
49. Thomas A.J., Davis S., Morris C., Jackson E., Harrison R., O'brien J.T. Increase in interleukin-1beta in late-life depression. Am J Psychiatry 2005, 162:175-177.
50. Trapp B.D., Wujek J.R., Criste G.A., Jalabi W., Yin X., Kidd G.J., Stohlman S., Ransohoff R. Evidence for synaptic stripping by cortical microglia. Wiley Interscience 2006, 55:360-368.
51. Tynan R.J., Naicker S., Hinwood M., Nalivaiko E., Buller K.M., Pow D.V., Day T.A., Walker F.R. Chronic stress alters the density and morphology of microglia in a subset of stress-responsive brain regions. Brain Behav Immun 2010, 24:1058-1068.
52. Tynan R.J., Weidenhofer J., Hinwood M., Cairns M.J., Day T.A., Walker F.R. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun 2012, 26.
53. Vollmar P., Haghikia A., Dermietzel R., Faustmann P.M. Venlafaxine exhibits an anti-inflammatory effect in an inflammatory co-culture model. Int J Neuropsychopharmacol 2008, 11:111-117.
54. Wang Y., Lawson M.A., Dantzer R., Kelley K.W. LPS-induced indoleamine 2,3-dioxygenase is regulated in an interferon-gamma-independent manner by a JNK signaling pathway in primary murine microglia. Brain Behav Immun 2010, 24:201-209.
55. Wang Y., Yang F., Liu Y.F., Gao F., Jiang W. Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neurosci Lett 2011, 499:74-79.
56. Warner-Schmidt J.L., Vanover K.E., Chen E.Y., Marshall J.J., Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. PNAS 2011, 27:11297-11298.
57. Wei Y., Zhi-Hong W., Gui-Xing Q., Bin Y., Jun C., Yi-Peng W. ERK inhibition modulates rat annulus fibrosus cell response to IL-1. Spine (Phila Pa 1976) 2013.
58. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005, 10:538-544.
59. Widner B., Laich A., Sperner-Unterweger B., Ledochowski M., Fuchs D. Neopterin production, tryptophan degradation, and mental depression - what is the link?. Brain Behav Immun 2002, 16:590-595.
60. Wolfe F., Michaud K. Predicting depression in rheumatoid arthritis: the signal importance of pain extent and fatigue, and comorbidity. Arthritis Rheum 2009, 61:667-673.
61. Zunszain P.A., Anacker C., Cattaneo A., Choudhury S., Musaelyan K., Myint A.M., Thuret S., Price J., et al. Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 2012, 37:939-949.